SciBX: Science-Business eXchange Contents: December 4 2014, Volume 7 / Issue 46

If you are unable to see the message below, click here to view.

Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The November 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Roche TABLE OF CONTENTS December 4 2014, Volume 7 / Issue 46 Analysis Cover Story Translational Notes Tools The Distillery: Therapeutics Autoimmune disease Cancer Cardiovascular disease Endocrine/metabolic disease Infectious disease Inflammation Neurology Pulmonary disease The Distillery: Techniques Assays and screens Disease models Drug platforms Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The November 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Indus Biotech   Analysis Cover Story Top GPCRs' grand plans Stephen Parmley doi:10.1038/scibx.2014.1337 A public-private precompetitive consortium aims to expand the number of known GPCR structures from 26 to over 200. Full Text | PDF Translational Notes Top Merck Encycles through Canada Michael J. Haas doi:10.1038/scibx.2014.1338 The first disclosed grant under Merck's 2013 initiative to fund Canadian innovation will support lead optimization of Encycle Therapeutics' macrocycle program for IBD. Full Text | PDF Incubating innovation Steve Edelson doi:10.1038/scibx.2014.1339 Two years ago, Janssen formed an internal incubator to solve a key problem: managing discoveries outside its own therapeutic areas. Incubator heads recently talked with SciBX about its progress so far. Full Text | PDF Tools Top Roche's heart for diabetes Benjamin Boettner doi:10.1038/scibx.2014.1340 Roche scientists have developed a cell-based model of diabetic cardiomyopathy, but they say it is only step one en route to a system that properly represents ventricles of a diseased heart. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top IL-23 doi:10.1038/scibx.2014.1341 In vitro and mouse studies suggest an alphabody scaffold protein with high affinity for IL-23 could help treat psoriasis. Full Text | PDF Cancer Top Pseudomonas aeruginosa exotoxin; IL-13 receptor α2 (IL-13RA2; IL-13R; CD213A2) doi:10.1038/scibx.2014.1342 Engineered P. aeruginosa exotoxin–producing neural stem cells could help treat glioblastoma multiforme (GBM). Full Text | PDF Inhibitor of κ-light polypeptide gene enhancer in B cells kinase-ε (IKBKE; IKKε); Janus kinase (JAK) doi:10.1038/scibx.2014.1343 In vitro and mouse studies suggest inhibiting IKBKE could help treat a subset of triple-negative breast cancers (TNBCs). Full Text | PDF Toll-like receptor 4 (TLR4); high mobility group box 1 (HMGB1) doi:10.1038/scibx.2014.1344 In vitro and mouse studies suggest inhibiting TLR4 or its ligand HMGB1 could help prevent metastasis. Full Text | PDF V-set domain containing T cell activation inhibitor 1 (B7-H4; VTCN1) doi:10.1038/scibx.2014.1345 Studies in mice and patient samples suggest antibodies against B7-H4 could help treat cancer. Full Text | PDF Fas apoptotic inhibitory molecule 3 (FAIM3; TOSO) doi:10.1038/scibx.2014.1346 In vitro and mouse studies suggest IgM-based conjugates targeting FAIM3 could help treat CLL. Full Text | PDF Adenomatous polyposis coli (APC); BH3 interacting domain death agonist (BID) doi:10.1038/scibx.2014.1347 Studies in mice and patient samples suggest activating BID could help prevent colorectal cancer in patients who carry mutations in the APC tumor suppressor. Full Text | PDF Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K) doi:10.1038/scibx.2014.1348 Studies in mice and patient samples suggest an anti-KIR3DL2 antibody could help treat the mycosis fungoides and Sézary syndrome subtypes of CTCL, which overexpress KIR3DL2. Full Text | PDF Cardiovascular disease Top Myosin regulatory light chain interacting protein (MYLIP; MIR; IDOL); liver X receptor (LXR) doi:10.1038/scibx.2014.1349 Nonhuman primate studies suggest combining MYLIP inhibitors with LXR agonists could help treat atherosclerosis. Full Text | PDF SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 5 (SMARCA5; SNF2H); farnesyltransferase CAAX box-β (FNTB); microRNA-99 (miR-99); miR-100; microRNA let-7 (MIRLET7; LET-7) doi:10.1038/scibx.2014.1350 Zebrafish and mouse studies suggest upregulating SMARCA5 and FNTB could help recovery after MI. Full Text | PDF Endocrine/metabolic disease Top Not applicable doi:10.1038/scibx.2014.1351 Rat studies suggest a glucosylflavonoid compound derived from the Genista tenera plant could help treat diabetes. Full Text | PDF Infectious disease Top S. aureus catabolite control protein E (ccpE) doi:10.1038/scibx.2014.1352 In vitro and mouse studies suggest activating ccpE could help treat Staphylococcus infection. Full Text | PDF Inflammation Top MicroRNA-19a (miR-19a) doi:10.1038/scibx.2014.1353 Studies in mice and patient samples suggest inhibition of miR-19a could help treat asthma. Full Text | PDF Neurology Top MicroRNA-188-3p (miR-188-3p); monoacylglycerol lipase (MAGL); β-site APP-cleaving enzyme 1 (BACE1) doi:10.1038/scibx.2014.1354 Studies in human samples and mice suggest miR-188-3p could help treat AD. Full Text | PDF Transient receptor potential cation channel subfamily M member 2 (TRPM2); β-amyloid 40 (Aβ40); poly(ADP-ribose) polymerase (PARP) doi:10.1038/scibx.2014.1355 In vitro and mouse studies suggest TRPM2 inhibitors could help treat AD. Full Text | PDF Ras/RAF/MEK/ERK pathway; Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) doi:10.1038/scibx.2014.1356 Mouse studies suggest inhibiting ERK activity could help treat cognitive deficits in Noonan syndrome, a disease caused by mutations in PTPN11 and other Ras/RAF/MEK/ERK pathway genes. Full Text | PDF Dynamin 1-like (DNM1L; DRP1) doi:10.1038/scibx.2014.1357 Mouse studies suggest inhibiting DNM1L could help treat PD. Full Text | PDF Pulmonary disease Top Maresin 1 (MaR1) doi:10.1038/scibx.2014.1358 In vitro and mouse studies suggest MaR1 could help protect against inflammation-induced lung injury. Full Text | PDF Distillery: Techniques Assays and screens Top Ex vivo detection of indirect therapeutic protein–small molecule drug interactions on the liver doi:10.1038/scibx.2014.1359 An ex vivo method for detecting indirect effects of therapeutic proteins on liver cells could help identify protein drugs that mask toxicities of coadministered small molecule drugs. Full Text | PDF Screening for diabetic cardiomyopathy (DCM) therapies in induced pluripotent stem (iPS) cell–derived cardiomyocytes doi:10.1038/scibx.2014.1360 iPS cell–derived cardiomyocytes could be used to screen for therapies to treat DCM. Full Text | PDF Disease models Top Mice from the Collaborative Cross (CC) resource as models of Ebola viral infection doi:10.1038/scibx.2014.1361 Mice from the CC resource could help identify markers of sensitivity and resistance to Ebola viral infection. Full Text | PDF Mouse model of immune complex–mediated kidney disease doi:10.1038/scibx.2014.1362 A mouse model of immune complex–mediated kidney disease could help identify new therapeutic strategies to treat the condition. Full Text | PDF Drug platforms Top Automated, in vitro generation of specific neuronal subtypes from human pluripotent stem cells doi:10.1038/scibx.2014.1363 An automated, in vitro protocol for generating neuronal subtypes from human pluripotent stem cells could be useful for developing cellular therapies to treat neurological diseases. Full Text | PDF Phage-assisted continuous evolution (PACE) to identify and predict drug-resistant protease mutations caused by protease inhibitors doi:10.1038/scibx.2014.1364 An in vitro method of directed evolution called PACE could help identify and predict drug-resistant protease mutations caused by protease inhibitors. Full Text | PDF Screening platform to produce high-affinity nanobodies doi:10.1038/scibx.2014.1365 A platform that uses high throughput DNA sequencing and mass spectrometric analysis of variable domains from immunized llamas could be used to develop high-affinity nanobody reagents and therapeutics. Full Text | PDF Top

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.